Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Allergan To Discuss Tazoral Psoriasis Non-Inferiority Study With FDA

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA deems oral tazarotene "not approvable." In addition to a non-inferiority study, Allergan must develop an "acceptable" risk management program and resolve manufacturing problems.

You may also be interested in...



Allergan To Conduct Additional Tazoral Pivotal Trial

Allergan receives a written response from FDA concerning the company's request for dispute resolution over the oral tazarotene NDA, which is "not approvable" at the agency. In addition to the new clinical trial, Allergan will supplement pharmacokinetic and toxicology data.

Allergan To Conduct Additional Tazoral Pivotal Trial

Allergan receives a written response from FDA concerning the company's request for dispute resolution over the oral tazarotene NDA, which is "not approvable" at the agency. In addition to the new clinical trial, Allergan will supplement pharmacokinetic and toxicology data.

Allergan, FDA To Meet On Tazoral NDA Deficiencies By Year-End

The meeting follows a Sept. 24 "not approvable" letter for the psoriasis treatment tazarotene. Allergan says the meeting is needed to provide insight into trial design for a non-inferiority trial.

Topics

UsernamePublicRestriction

Register

LL1135307

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel